Dr. Shlomit Yehudai-Reshef, PhD, is currently the Director of the Clinical Research Institute at Rambam (CRIR). She completed her PhD in biology in 2003 at the Technion – Israel Institute of Technology (Haifa, Israel), and subsequently conducted postdoctoral research at Cornell University in New York, USA, from 2003 to 2006.
In 2008, Dr. Yehudai-Reshef joined the Physics Department at the Technion as a research associate, where she focused on bio-physical research. This experience led her to develop expertise in live-cell imaging and image analysis.
In 2012, Dr. Yehudai-Reshef became a part of the Hematology Research Center at the Rambam Health Care Campus in Haifa, Israel. There, she established the Leukemia Research Laboratory, which is affiliated with the CRIR.
Since 2016, Dr. Yehudai-Reshef has been a member of the CRIR, and in 2018, she assumed the role of CRIR Director. She is deeply committed to fostering collaboration between physicians and scientists, and she actively promotes translational research. Driven by her vision, she aims to establish a national translational research ecosystem led by healthcare researchers. Furthermore, she actively encourages global collaborations and strives for scientific excellence within the CRIR.
Alongside her research and leadership responsibilities, Dr. Yehudai-Reshef holds the position of Senior Lecturer at the Ruth and Bruce Rappaport Faculty of Medicine at the Technion in Haifa, Israel. She recognizes the importance of promoting educational programs and nurturing the next generation of researchers.
In 2015, Dr. Yehudai-Reshef founded "Nevia Bio (formerly Gina Life)," a FemTech company dedicated to developing a platform for early diagnosis of various diseases in women. Currently, she serves as the Chief Scientist and a board member of the company.
Dr. Yehudai-Reshef's research approach is characterized by its multidisciplinary nature, drawing from her diverse expertise, skills, and knowledge. This combination contributes to her innovative and creative research endeavors, as she continues to make significant contributions in her field.